Cargando…

METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of renal malignancy. Methyltransferase like 13 (METTL13) functions as an oncogene in most of human cancers, but its function and mechanism in ccRCC remains unreported. METHODS: qRT-PCR, western blotting and im...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhuonan, Sun, Tianshui, Piao, Chiyuan, Zhang, Zhe, Kong, Chuize
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120818/
https://www.ncbi.nlm.nih.gov/pubmed/33985542
http://dx.doi.org/10.1186/s12967-021-02879-2
_version_ 1783692184948572160
author Liu, Zhuonan
Sun, Tianshui
Piao, Chiyuan
Zhang, Zhe
Kong, Chuize
author_facet Liu, Zhuonan
Sun, Tianshui
Piao, Chiyuan
Zhang, Zhe
Kong, Chuize
author_sort Liu, Zhuonan
collection PubMed
description BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of renal malignancy. Methyltransferase like 13 (METTL13) functions as an oncogene in most of human cancers, but its function and mechanism in ccRCC remains unreported. METHODS: qRT-PCR, western blotting and immunohistochemistry were used to detect METTL13’s expression in tissues. The effects of METTL13 on ccRCC cells’ growth and metastasis were determined by both functional experiments and animal experiments. Weighted gene co-expression network analysis (WGCNA) was performed to annotate METTL13’s functions and co-immunoprecipitation (co-IP) was used to determine the interaction between METTL13 and c-Myc. RESULTS: METTL13 was underexpressed in ccRCC tissues compared to normal kidney tissues and its low expression predicted poor prognosis for ccRCC patients. The in vitro studies showed that knockdown and overexpression of METTL13 respectively led to increase and decrease in ccRCC cells’ proliferation, viability, migratory ability and invasiveness as well as epithelial-mesenchymal transition (EMT). The in vivo experiment demonstrated the inhibitory effect that METTL13 had on ccRCC cells’ growth and metastasis. Bioinformatic analyses showed various biological functions and pathways METTL13 was involved in. In ccRCC cells, we observed that METTL13 could negatively regulate PI3K/AKT/mTOR/HIF-1α pathway and that it combined to c-Myc and inhibited c-Myc protein expression. CONCLUSIONS: In general, our finding suggests that high expression of METTL13 is associated with favorable prognosis of ccRCC patients. Meanwhile, METTL13 can inhibit growth and metastasis of ccRCC cells with participation in multiple potential molecular mechanisms. Therefore, we suggest METTL13 can be a new diagnostic and therapeutic target for ccRCC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02879-2.
format Online
Article
Text
id pubmed-8120818
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81208182021-05-17 METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression Liu, Zhuonan Sun, Tianshui Piao, Chiyuan Zhang, Zhe Kong, Chuize J Transl Med Research BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of renal malignancy. Methyltransferase like 13 (METTL13) functions as an oncogene in most of human cancers, but its function and mechanism in ccRCC remains unreported. METHODS: qRT-PCR, western blotting and immunohistochemistry were used to detect METTL13’s expression in tissues. The effects of METTL13 on ccRCC cells’ growth and metastasis were determined by both functional experiments and animal experiments. Weighted gene co-expression network analysis (WGCNA) was performed to annotate METTL13’s functions and co-immunoprecipitation (co-IP) was used to determine the interaction between METTL13 and c-Myc. RESULTS: METTL13 was underexpressed in ccRCC tissues compared to normal kidney tissues and its low expression predicted poor prognosis for ccRCC patients. The in vitro studies showed that knockdown and overexpression of METTL13 respectively led to increase and decrease in ccRCC cells’ proliferation, viability, migratory ability and invasiveness as well as epithelial-mesenchymal transition (EMT). The in vivo experiment demonstrated the inhibitory effect that METTL13 had on ccRCC cells’ growth and metastasis. Bioinformatic analyses showed various biological functions and pathways METTL13 was involved in. In ccRCC cells, we observed that METTL13 could negatively regulate PI3K/AKT/mTOR/HIF-1α pathway and that it combined to c-Myc and inhibited c-Myc protein expression. CONCLUSIONS: In general, our finding suggests that high expression of METTL13 is associated with favorable prognosis of ccRCC patients. Meanwhile, METTL13 can inhibit growth and metastasis of ccRCC cells with participation in multiple potential molecular mechanisms. Therefore, we suggest METTL13 can be a new diagnostic and therapeutic target for ccRCC in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02879-2. BioMed Central 2021-05-13 /pmc/articles/PMC8120818/ /pubmed/33985542 http://dx.doi.org/10.1186/s12967-021-02879-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Zhuonan
Sun, Tianshui
Piao, Chiyuan
Zhang, Zhe
Kong, Chuize
METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title_full METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title_fullStr METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title_full_unstemmed METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title_short METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
title_sort mettl13 inhibits progression of clear cell renal cell carcinoma with repression on pi3k/akt/mtor/hif-1α pathway and c-myc expression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120818/
https://www.ncbi.nlm.nih.gov/pubmed/33985542
http://dx.doi.org/10.1186/s12967-021-02879-2
work_keys_str_mv AT liuzhuonan mettl13inhibitsprogressionofclearcellrenalcellcarcinomawithrepressiononpi3kaktmtorhif1apathwayandcmycexpression
AT suntianshui mettl13inhibitsprogressionofclearcellrenalcellcarcinomawithrepressiononpi3kaktmtorhif1apathwayandcmycexpression
AT piaochiyuan mettl13inhibitsprogressionofclearcellrenalcellcarcinomawithrepressiononpi3kaktmtorhif1apathwayandcmycexpression
AT zhangzhe mettl13inhibitsprogressionofclearcellrenalcellcarcinomawithrepressiononpi3kaktmtorhif1apathwayandcmycexpression
AT kongchuize mettl13inhibitsprogressionofclearcellrenalcellcarcinomawithrepressiononpi3kaktmtorhif1apathwayandcmycexpression